AstraZeneca reports revenue growth, pipeline tweaks as it ponders price cuts, direct-to-patient sales

AstraZeneca’s cancer drugs, particularly Imfinzi, buoyed the company to its largest quarterly revenues to date, at $14.5 billion. The company also said Tuesday it cut a handful of assets from its pipeline, notably the lead ...